Discounted Cash Flow
10x Genomics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $71.1m | $-18.8m | $-14.5m | -26.4% | — |
| 2018 | $146.3m (105.8%) | $-112.5m (-499.5%) | $-82.7m (-472.1%) | -76.9% (-191.3%) | — |
| 2019 | $245.9m (68.1%) | $-31.3m (72.2%) | $-8.1m (90.2%) | -12.7% (83.5%) | $-0.80 |
| 2020 | $298.8m (21.5%) | $-542.7m (-1636.7%) | $-254.6m (-3037.0%) | -181.6% (-1329.0%) | $-5.37 (-571.2%) |
| 2021 | $490.5m (64.1%) | $-58.2m (89.3%) | $-122.7m (51.8%) | -11.9% (93.5%) | $-0.53 (90.1%) |
| 2022 | $516.4m (5.3%) | $-166.0m (-185.1%) | $-165.3m (-34.7%) | -32.1% (-170.8%) | $-1.46 (-175.5%) |
| 2023 | $618.7m (19.8%) | $-255.1m (-53.7%) | $-63.8m (61.4%) | -41.2% (-28.3%) | $-2.18 (-49.3%) |
| 2024 | $610.8m (-1.3%) | $-182.6m (28.4%) | $-5.7m (91.0%) | -29.9% (27.5%) | $-1.52 (30.3%) |
| 2025 | $642.8m (5.2%) | $-43.5m (76.2%) | $130.1m (2371.2%) | -6.8% (77.3%) | $-0.35 (77.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.